Phenotypic quantitative features of patients with acute myeloid leukemia

Neoplasma

Volumn 53, Issue 2, 2006, Pages 155-160

  Pereira, F G ^a   Metze, K ^a   Costa, F P S ^a   Lima, C S P ^a   Lorand Metze, I ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Acute myeloid leukemia; Antigen expression; Flow cytometry; Immunophenotype; Sub populations

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOGENETICS; CYTOLOGY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE; MALE; MYELOID LEUKEMIA; PHENOTYPE;

EID: 33645467334     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ORFAO A, ORTUNO FJ, SANTIAGO M, LOPEZ A, SAN MIGUEL J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry 2004; 58A: 62-71.
2. BASSO G, BULDINI B, DE ZEN L, ORFAO A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675-692.
3. BENÉ MC. Immunophenotyping of acute leukaemias. Immunology Lett 2005; 15: 9-21. Review.
4. CASASNOVAS RO, SLIMANE FK, GARAND R, FAURE GC, CAMPOS L et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003; 17: 515-527.
5. CHANG H, SALMA F, YI Q, PATTERSON B, BRIEN B, MINDEN MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004; 28: 43-48.
6. DANESHBOD Y, AMIRGHOFRAN Z, TABEI SZ. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 2005; 52: 109-114.
7. KLOBUSICKA M, KUSENDA J, BABUSIKOVA O. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia at diagnosis. Neoplasma 2005; 52: 211-218.
8. PIEDRAS J, BARRALES-BENITEZ O, LOPEZ-KARPOVITCH X. Classification of acute leukemias according to the first latin-american consensus conference for the immunophenotyping of leukemias. La Revista de Investigación Clinica 2000; 52: 524-528.
9. RASPADORI D, LAURIA F, VENTURA MA, RONDELLI D, VISANI G et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997; 21: 603-607.
10. REGO MF, PINHEIRO GS, METZE K, LORAND-METZE I. Acute leukemias in Piaui: comparison with features observed in other regions of Brazil. Br J Med Biol Res 2003; 36: 331-337.
11. REPP R, SCHAEKEL U, HELM G, THIEDE C, SOUCEK S et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry 2003; 53B: 11-19.
12. SCHABATH R, RATEI R, LUDWIG WD. The prognostic significance of antigen expression in leukaemia. Best Pract Res Clin Haematol 2003; 16: 613-628.
13. TALLMAN MS, KIM HT, PAIETTA E, BENNETT JM, DEWALD G et al. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22: 1276-1286.
14. VALET G, REPP R, LINK H, EHNINGER A, GRAMATZKI MM. Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters. Cytometry 2003; 53B: 4-10.
15. BUCHNER T, URBANITZ D, EMMERICH B, FISCHER JT, FULLE HH et al. Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 1982; 6: 827-831.
16. PAGNANO KB, TRAINA F, TAKAHASHI T, OLIVEIRA GB, ROSSINI MS et al. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. Sao Paulo Med J 2000; 118: 173-178.
17. VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
18. LEGRAND O, PERROT JY, BAUDARD M, CORDIER A, LAUTIER R et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870-877.
19. ALTMAN DG, ANDERSEN PK. Bootstrap investigation of the stability of a Cox regression model. Statistics in Medicine 1989; 8: 771-783.
20. LORAND-METZE I, PINHEIRO MP, RIBEIRO E, DE PAULA EV, METZE K. Factors influencing survival in myelodysplastic syndromes in a brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004; 28: 587-594.
21. METZE K, OLIVEIRA GB, PEREIRA FG, ADAM RL, LORAND-METZE I. Spontaneous apoptosis in chronic lymphoid leukemia is not an independent prognostic factor for stability of disease when compared with AgNOR and TTM. Cell Oncol 2005; 27: 199-201.
22. METZE K, LOBO AM, LORAND-METZE I. Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. Int J Cancer 2000; 89: 440-443.
23. METZE K, SILVA RC, ADAM RA, LEITE NJ, PEREIRA FG, LORAND-METZE I. Relation between chromatin texture and phenotype in acute leukemias. Cell Oncol 2005; 27: 112.
24. CAMPANA D, BEHM FG. Immunophenotyping of leukemia. J Immunol Meth 2000; 243: 59-75.
25. THALHAMMER-SCHERRER R, MITTERBAUER G, SIMONITSCH I, JAEGER U, LECHNER K et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380-389.
26. VOSKOVA D, VALEKOVA L, FEDOROVA J, HUDECEK J, KUBISZ P. Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometric analysis. Neoplasma 2003; 50: 422-427.
27. DUNPHY CH, ORTON SO, MANTELL J. Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. Am J Clin Pathol 2004; 122: 865-874.
28. FERGEDAL M, ASTROM M, TIDEFELT U, KARLSSON MG. Differences in CD 14 and alpha-naphthyl acetate esterase positivity and relation to prognosis in AML. Leuk Res 1998; 22: 25-30.
29. NORGAARD JM, OLESEN LH, OLESEN G, MEYER K, KRISTENSEN JS et al. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001; 67: 221-229.
30. PEFFAULT DE LATOUR R, LEGRAND O, MOREAU D, PERROT JY, BLANC CM et al. Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxydase in acute myeloid leukaemia: interests of a new positivity threshold. Br J Haematol 2003; 122: 211-216.
31. VAN DER VELDEN VHJ, BOECKX N, JEDEMA I, TE MARVELDE JG, HOOGEVEEN PG et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18: 983-988.
32. BOROWITZ MJ, SHUSTER J, CARROLL AJ, NASH M, LOOK AT et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood 1997; 89: 3960-3966.
33. NAKAMURA A, TSURUSAWA M, KATO A, TAGA T, HATAE Y et al. Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 2001; 42: 393-398.